


Healthcare | Small Cap
Sanofi India Ltd. presents a mixed financial picture, characterized by exceptional stability but significant performance challenges. The company's greatest strength is its virtually debt-free status, which provides a strong cushion against financial risks and economic volatility. Operationally, it appears to manage its inventory and customer payments with notable efficiency. However, these strengths are contrasted by considerable weaknesses in key areas. The company is currently experiencing a lack of growth across revenues, profits, and assets, indicating a period of stagnation. Profitability is a major concern, with margins and returns on investment being very low. Furthermore, its capacity to cover short-term expenses with available liquid cash is limited. The future outlook is one of stability without growth; while the company is not in immediate financial danger due to its low debt, its inability to expand and generate profits poses a significant long-term challenge.
Sanofi India Ltd. presents a mixed financial picture, characterized by exceptional stability but significant performance challenges. The company's greatest strength is its virtually debt-free status, which provides a strong cushion against financial risks and economic volatility. Operationally, it appears to manage its inventory and customer payments with notable efficiency. However, these strengths are contrasted by considerable weaknesses in key areas. The company is currently experiencing a lack of growth across revenues, profits, and assets, indicating a period of stagnation. Profitability is a major concern, with margins and returns on investment being very low. Furthermore, its capacity to cover short-term expenses with available liquid cash is limited. The future outlook is one of stability without growth; while the company is not in immediate financial danger due to its low debt, its inability to expand and generate profits poses a significant long-term challenge.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
24.92
Industry Median
40.03
Small Cap Median
31.25
P/E RATIO
18.66
P/B RATIO
8.96
Industry Median
12.59
Small Cap Median
8.96
P/S RATIO
3.88
Industry Median
8.14
Small Cap Median
3.88
Others
PEG RATIO
0.00
EV/EBITDA RATIO
13.22
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹3352.6 as on Aug 6, 2026.
The company's growth prospects appear weak across the board. The analysis reveals a lack of expansion in key areas, including sales, operating profits, and net income. Additionally, the company is not significantly growing its asset base, which suggests limited investment in future expansion. This overall stagnation is a significant concern, as it points to a business that is struggling to increase its market share or operational scale. A lack of growth can impact long-term competitiveness and shareholder value.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | |||||
| Operating Profit Growth Rate | |||||
| Earnings Per Share (EPS) Growth | |||||
| Asset Growth Rate | |||||
| Net Income Growth Rate |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 34.93 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 21.40 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 34.29 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 35.92 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 38.74 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 40.87 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 29.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Hikal Ltd | 7.13 | -55.92 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | Shilpa Medicare Ltd | 5.94 | 59.39 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 10 | Natco Pharma Ltd | 5.69 | 11.52 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 16.53 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 33.85 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Orchid Pharma Ltd | 4.85 | 246.31 | Neutral | 41.00 | 8.91 | 21.00 |
| 14 | Sequent Scientific Ltd | 4.61 | 313.39 | Overvalued | 162.00 | 1.74 | 32.00 |
| 15 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.53 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 16 | Zota Health Care Ltd | 3.97 | -58.38 | Neutral | 19.00 | 8.06 | -74.00 |
| 17 | Sanofi India Ltd | 3.45 | 18.66 | Neutral | 491.00 | 134.52 | 413.00 |
| 18 | Procter & Gamble Health Ltd | 3.45 | 30.81 | Neutral | 457.00 | 196.94 | 327.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤5th Mar 26
Investor Conference Call – Feb 26, 2026
NEUTRAL SENTIMENT
Quarterly Report⬤25th Feb 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT